Profiling therapeutic precision

The ideal drug would exhibit pure action at a single site. Such pinpoint precision would work as if a single gene were switched off. Rosetta Inpharmatics is pursuing technology aimed at helping drug designers determine if their compounds have such precision.

The approach uses cDNAs from yeast knock-out